The price of PetIQ Inc. (NASDAQ:PETQ) shares last traded on Wall Street rose 1.66% to $11.03.
Based on available information, 6 analysts follow PetIQ Inc. (NASDAQ:PETQ). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $30.00 and a low of $16.00, we find $25.50. Given the previous closing price of $10.85, this indicates a potential upside of 135.02 percent. PETQ stock price is now 3.48% away from the 50-day moving average and -17.19% away from the 200-day moving average. The market capitalization of the company currently stands at $325.27M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 1 rate the stock a hold while 4 rate it a buy. Brokers who have rated the stock have averaged $24.25 as their price target over the next twelve months.
On November 30, 2021, The Benchmark Company recently initiated its ‘Buy’ rating on the stock quoting a target price of $30, while ‘Jefferies’ rates the stock as ‘Buy’.
In other news, Herrman Robert Michael, GENERAL COUNSEL AND SECRETARY bought 1,376 shares of the company’s stock on Sep 07. The stock was bought for $14,998 at an average price of $10.90. Upon completion of the transaction, the GENERAL COUNSEL AND SECRETARY now directly owns 9,050 shares in the company, valued at $99821.5. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 06, PRESIDENT Smith Michael A bought 10,000 shares of the business’s stock. A total of $97,100 was incurred on buying the stock at an average price of $9.71. This leaves the insider owning 38,155 shares of the company worth $0.42 million. Insiders disposed of 14,970 shares of company stock worth roughly $0.17 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PETQ stock. A new stake in PetIQ Inc. shares was purchased by ZAZOVE ASSOCIATES LLC during the first quarter worth $5,846,000. BOOTHBAY FUND MANAGEMENT, LLC invested $1,999,000 in shares of PETQ during the first quarter. In the first quarter, ALPHACENTRIC ADVISORS LLC acquired a new stake in PetIQ Inc. valued at approximately $1,974,000. QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in PETQ for approximately $1,569,000. EXODUSPOINT CAPITAL MANAGEMENT, LP purchased a new stake in PETQ valued at around $1,283,000 in the second quarter.
A candlestick chart of PetIQ Inc. (NASDAQ: PETQ) showed a price of $10.80 on Tuesday morning. During the past 12 months, PetIQ Inc. has had a low of $6.66 and a high of $25.40. As of last week, the company has a debt-to-equity ratio of 2.13, a current ratio of 2.90, and a quick ratio of 1.60. The fifty day moving average price for PETQ is $10.66 and a two-hundred day moving average price translates $13.32 for the stock.
The latest earnings results from PetIQ Inc. (NASDAQ: PETQ) was released for Jun, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.51, beating analysts’ expectations of $0.34 by 0.17. This compares to -$0.29 EPS in the same period last year. The net profit margin was -5.90% and return on equity was -22.40% for PETQ. The company reported revenue of $209.72 million for the quarter, compared to $210.53 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.38 percent. For the current quarter, analysts expect PETQ to generate $204.33M in revenue.
PetIQ Inc.(PETQ) Company Profile
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at 2,900 community clinics and wellness centers hosted at pet retailers across 42 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
